Cytosorbents Corporation

Equities

CTSO

US23283X2062

Advanced Medical Equipment & Technology

Market Closed - Nasdaq 04:00:00 2024-03-27 pm EDT 5-day change 1st Jan Change
0.9299 USD +4.48% Intraday chart for Cytosorbents Corporation +7.05% -16.23%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Cytosorbents Corporation Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Earnings Flash (CTSO) CYTOSORBENTS Reports Q4 Revenue $8.7M, vs. Street Est of $9.8M MT
Transcript : Cytosorbents Corporation, Q4 2023 Earnings Call, Mar 14, 2024
Cytosorbents Corporation Reports Excellent Outcomes from A Groundbreaking Randomized Controlled Trial Using Cytosorb® Blood Purification During Heart Transplant, Recently Published in the European Society of Cardiology Journal, Esc Heart Failure CI
North American Morning Briefing : Stock Futures Struggle After Weak China Data DJ
HC Wainwright Downgrades Cytosorbents to Neutral From Buy, Cuts Price Target to $1 From $5.50 MT
S&P 500 ekes out meager gains, flirts with bull market confirmation RE
Sector Update: Health Care Stocks Rise in Late Afternoon MT
Top Midday Decliners MT
Wall St inches higher as S&P 500 flirts with bull market confirmation RE
US Stocks Holding on for Small Thursday Gains, Again Drifting Near Record Highs MT
US Stocks Adding to Recent Gain Amid New Economic Data MT
B. Riley Trims Price Target on Cytosorbents to $3 From $4, Maintains Buy Rating MT
US STOCKS -Wall Street edges higher as year end approaches, rate cuts in focus RE
Sector Update: Health Care Stocks Steady Premarket Thursday MT
Sector Update: Health Care MT
Exchange-Traded Funds Higher, Equity Futures Mixed Pre-Bell Thursday MT
Cytosorbents Says DrugSorb-ATR Study Misses Primary Effectiveness Endpoint; Shares Fall Pre-Bell MT
Sector Update: Health Care Stocks Advance Thursday Afternoon MT
Sector Update: Health Care MT
Cytosorbents Corporation Provides Update on the Star-T Trial and Reports Final Independent Data and Safety Monitoring Board Recommendation CI
Cytosorbents Corporation announced that it expects to receive $10.28501 million in funding CI
Transcript : Cytosorbents Corporation, Q3 2023 Earnings Call, Nov 09, 2023
Earnings Flash (CTSO) CYTOSORBENTS Posts Q3 Revenue $8.8M, vs. Street Est of $9.32M MT
Cytosorbents Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Chart Cytosorbents Corporation
More charts
CytoSorbents Corporation is engaged in the treatment of life-threatening conditions in intensive care and cardiac surgery using blood purification via its polymer adsorption technology. Its lead product, CytoSorb, is an extracorporeal cytokine absorber, designed to reduce the cytokine storm or cytokine release syndrome that could otherwise cause massive inflammation, organ failure and death in common critical illnesses, such as sepsis, burn injury, trauma, lung injury, cytokine release syndrome due to cancer immunotherapy, and pancreatitis. Its other products include CytoSorb, animal-targeted VetResQ, DrugSorb-ATR, ECOS-300CY. Its other product candidates under development, including CytoSorb XL, BetaSorb, ContrastSorb, DrugSorb, HemoDefend-RBC, HemoDefend-BGA, K+ontrol, and others consist of a cartridge containing adsorbent, porous polymer beads, although the polymers used in these devices are physically different.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
0.9299 USD
Average target price
2.667 USD
Spread / Average Target
+186.77%
Consensus
  1. Stock
  2. Equities
  3. Stock Cytosorbents Corporation - Nasdaq
  4. News Cytosorbents Corporation
  5. Cytosorbents : Health Care Stocks Inch Higher Ahead of Wednesday Open